Literature DB >> 1911179

The current status of scientific research and hormonal treatments for carcinoma of the prostate.

J Waxman, A Saini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1911179      PMCID： PMC1977666          DOI： 10.1038/bjc.1991.324

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  22 in total

1.  Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.

Authors:  F Labrie; A Dupont; M Giguere; J P Borsanyi; Y Lacourciere; A Belanger; R Lachance; J Emond; G Monfette
Journal:  J Steroid Biochem       Date:  1987       Impact factor: 4.292

Review 2.  Gonadotrophin hormone releasing analogues open new doors in cancer treatment.

Authors:  J Waxman
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-31

3.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

Authors:  E D Crawford; M A Eisenberger; D G McLeod; J T Spaulding; R Benson; F A Dorr; B A Blumenstein; M A Davis; P J Goodman
Journal:  N Engl J Med       Date:  1989-08-17       Impact factor: 91.245

4.  Expression of a transfected v-Harvey-ras oncogene in a Dunning rat prostate adenocarcinoma and the development of high metastatic ability.

Authors:  B Treiger; J Isaacs
Journal:  J Urol       Date:  1988-12       Impact factor: 7.450

5.  Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines.

Authors:  G L Morris; J G Dodd
Journal:  J Urol       Date:  1990-06       Impact factor: 7.450

6.  Expression of cellular oncogenes in human prostatic carcinoma cell lines.

Authors:  A W Rijnders; J A van der Korput; G J van Steenbrugge; J C Romijn; J Trapman
Journal:  Biochem Biophys Res Commun       Date:  1985-10-30       Impact factor: 3.575

7.  Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia.

Authors:  W H Fleming; A Hamel; R MacDonald; E Ramsey; N M Pettigrew; B Johnston; J G Dodd; R J Matusik
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

8.  Expression of ras oncogene p21 in prostate cancer.

Authors:  M V Viola; F Fromowitz; S Oravez; S Deb; G Finkel; J Lundy; P Hand; A Thor; J Schlom
Journal:  N Engl J Med       Date:  1986-01-16       Impact factor: 91.245

9.  Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer.

Authors:  P N Plowman; L A Perry; T Chard
Journal:  Br J Urol       Date:  1987-03

10.  Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.

Authors:  M Pavone-Macaluso; H J de Voogt; G Viggiano; E Barasolo; B Lardennois; M de Pauw; R Sylvester
Journal:  J Urol       Date:  1986-09       Impact factor: 7.450
View more
  2 in total

Review 1.  Screening for prostate cancer. Implications for drug therapy.

Authors:  R H Harwood
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

Review 2.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.